NextCure reports marginal increase in 2025 net loss

NextCure

05/03/2026 21:17

Overview

Biopharmaceutical firm's net loss for 2025 was $55.8 mln, slightly up from 2024

Research and development expenses rose due to SIM0505 payments

General and administrative expenses decreased by $3 mln in 2025

Outlook

NextCure expects SIM0505 Phase 1 data in Q2 2026

Company plans to double U.S. trial sites in H2 2026

NextCure plans LNCB74 trial update in H2 2026

Result Drivers

R&D EXPENSES - Increased due to $18.5 mln of license fees and milestone payments for SIM0505, partially offset by lower costs related to deprioritized programs, lower preclinical development costs and lower personnel-related costs

Company press release: ID:nGNX96Vd4f

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$55.84 mln
FY Basic EPS
-$19.65
FY Income from Operations
-$57.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for NextCure Inc is $18.00, about 42.9% above its March 4 closing price of $12.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)